Plant Name: Hedysarum denticulatum
Taxonomic Information:
Plant ID: NPO4658
Plant Latin Name: Hedysarum denticulatum
Taxonomy Genus: Hedysarum
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| CDK8; CSNK2A1; | |
| AR; NR3C2; PGR; NR3C1; | |
| ESR2; | |
| HSD17B1; HSD11B1; | |
| HIF1A; | |
| SERPINA6; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Nuclear hormone receptor subfamily 3 group C | NR3C2 | Mineralocorticoid receptor | P08235 | CHEMBL1994 |
| Nuclear hormone receptor subfamily 3 group C | PGR | Progesterone receptor | P06401 | CHEMBL208 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | SERPINA6 | Corticosteroid binding globulin | P08185 | CHEMBL2421 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005496; steroid binding | 8.267E-13 | 1.800E-08 | AR, ESR2, HSD17B1, NR3C1, NR3C2, PGR, SERPINA6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.104E-10 | 8.016E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.570E-10 | 1.990E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.858E-09 | 5.780E-06 | AR, ESR2, NR3C1, NR3C2, PGR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.127E-09 | 8.512E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 5.027E-09 | 1.095E-05 | AR, CDK8, ESR2, NR3C1, NR3C2, PGR |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.622E-09 | 1.095E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 9.445E-08 | 1.143E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.876E-07 | 2.723E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
| BP | GO:0009987; cellular process | GO:0030518; intracellular steroid hormone receptor signaling pathway | 7.211E-07 | 6.039E-04 | AR, ESR2, NR3C1, PGR |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.019E-06 | 8.221E-04 | ACHE, AR, HSD17B1, NR3C1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.189E-06 | 9.249E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0022414; reproductive process | GO:0060748; tertiary branching involved in mammary gland duct morphogenesis | 2.459E-06 | 1.487E-03 | AR, PGR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.314E-06 | 1.804E-03 | CSNK2A1, HIF1A, NR3C1 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.993E-06 | 2.070E-03 | CYP19A1, CYP1A1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.916E-06 | 2.433E-03 | CYP1A1, CYP1A2 |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 5.085E-06 | 2.460E-03 | ACHE, AR, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, HIF1A, HSD11B1 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 7.418E-06 | 3.511E-03 | ACHE, CSNK2A1, CYP19A1, CYP1A1, HSD11B1, HSD17B1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 9.296E-06 | 4.208E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, HSD11B1, HSD17B1 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.097E-05 | 4.774E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, HSD11B1, NR3C2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.228E-05 | 4.950E-03 | CYP1A2, CYP2C19 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.219E-05 | 4.950E-03 | AR, ESR2, PGR |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.289E-05 | 8.593E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0000978; RNA polymerase II proximal promoter sequence-specific DNA binding | 2.369E-05 | 8.599E-03 | AR, ESR2, HIF1A, NR3C1, PGR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.236E-12 | 3.377E-10 | HSD11B1, HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.030E-07 | 1.408E-06 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.412E-09 | 1.725E-07 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.808E-07 | 4.928E-06 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 5.923E-06 | 4.857E-05 | CYP1A2, CYP1A1, CYP1B1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.430E-04 | 3.181E-03 | HSD11B1, HSD17B1, CYP1A2, CYP1A1, CYP2C19, CYP19A1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.062E-04 | 2.092E-03 | CYP1A2, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.539E-03 | 7.886E-03 | CYP1A2, CYP1A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.732E-03 | 7.889E-03 | CYP1A2, CYP2C19 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NR3C1; SERPINA6; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; PGR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR; |
| NA: NA | Male hypogonadism | NA | AR; |
| NA: NA | Obstructive airway diseases | NA | SERPINA6; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormonal contraceptives | Z30 | PGR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | NR3C2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR; |
| C00-D49: Neoplasms | Uterine leiomyoma | D25 | PGR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; |
| Z00-Z99: Factors influencing health status and contact with health services | Female contraception | Z30 | PGR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; NR3C2; |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; PGR; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Addison's disease | E27.1-E27.2 | NR3C2; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | NR3C1; SERPINA6; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; NR3C1; NR3C2; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | PGR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; NR3C1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; NR3C2; |
| C00-D49: Neoplasms | Advanced endometrium carcinoma | NA | PGR; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cerebral salt-wasting syndrome | E87.1 | NR3C2; |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1; |
| N00-N99: Diseases of the genitourinary system | Menstrual disorders | N91-N95 | PGR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | PGR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; CSNK2A1; ACHE; HIF1A; NR3C1; NR3C2; PGR; |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Advanced breast carcinoma | NA | PGR; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1; |
| C00-D49: Neoplasms | Endometrial cancer | C54.1 | PGR; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PGR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; |
| NA: NA | Non-infectious rhinitis | NA | NR3C1; |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | SERPINA6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | NR3C2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic macular edema | E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9 | SERPINA6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | NR3C1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| C00-D49: Neoplasms | Uterine fibroids | D25 | PGR; |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1; |
| N00-N99: Diseases of the genitourinary system | Gynecological disorder | N70-N98 | PGR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR; |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1; |
| N00-N99: Diseases of the genitourinary system | Chronic kidney disease | N18 | NR3C2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | NR3C1; |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | NR3C2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
